Literature DB >> 3094383

Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A.

N Perico, A Benigni, C Zoja, F Delaini, G Remuzzi.   

Abstract

Animals and humans undergoing a chronic treatment with cyclosporin A (CyA) show a reduction in glomerular filtration rate (GFR). The cause of this abnormality has not been established. Since CyA interferes with arachidonic acid (AA) metabolism in various cells, we wished to determine whether alterations in renal AA metabolites contribute to deteriorating renal function in rats on CyA. We show that chronic CyA treatment induces a progressive increase in the renal synthesis of thromboxane (TX) A2. This is a selective abnormality in that CyA does not influence the renal synthesis of prostaglandin E2 (PGE2) and prostacyclin (PGI2). A significant negative correlation has been found between TXB2 urinary excretion rate and inulin clearance. No correlation has been observed between TXB2 excretion and p-aminohippuric acid clearance. The withdrawal of CyA is followed by a normalization of both TXB2 urinary excretion rate and GFR. The administration of a selective TXA2 inhibitor, UK-38,485, resulted in a significant reduction in urinary excretion of TXB2 accompanied by a significant increase in GFR. We conclude that chronic treatment with CyA in rats is associated with a selective increase in renal TXA2 synthesis and suggest that this abnormality may play a role in the reduction of GFR.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094383     DOI: 10.1152/ajprenal.1986.251.4.F581

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

Review 1.  Cardiac transplantation. Selection, immunosuppression, and survival.

Authors:  L W Stevenson; H Laks; P I Terasaki; B D Kahan; D C Drinkwater
Journal:  West J Med       Date:  1988-11

Review 2.  Hypertension after renal transplantation.

Authors:  V Schwenger; M Zeier; E Ritz
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 3.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 4.  Cyclosporin-induced hypertension: incidence, pathogenesis and management.

Authors:  S J Taler; S C Textor; V J Canzanello; L Schwartz
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

5.  Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries.

Authors:  G S O'Neil; A H Chester; S Kushwaha; M Rose; S Tadjkarimi; M H Yacoub
Journal:  Br Heart J       Date:  1991-09

6.  Acute and chronic renal failure in liver transplantation.

Authors:  J McCauley; D H Van Thiel; T E Starzl; J B Puschett
Journal:  Nephron       Date:  1990       Impact factor: 2.847

7.  Renal injury induced by long-term administration of cyclosporin A to rats.

Authors:  T Bertani; N Perico; M Abbate; C Battaglia; G Remuzzi
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

Review 8.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

Review 9.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

10.  Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease.

Authors:  C Zoja; A Benigni; M Livio; A Bergamelli; S Orisio; M Abbate; T Bertani; G Remuzzi
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.